A study by Hong et al., in 2003, assessed the efficiency of the combination of β-glucan with mAbs against naturally occurring tumor antigens GD2 ganglioside or recombinant human MUC1 and demonstrated a CR3-mediated granulocyte-dependent significant tumor regression with the combination of β-glucan and mAbs in five different mouse models of tumor [119]. The gene discussed is CRIPTO3; the disease is neoplasm.